The Q2 results are directionally neutral for a pre-revenue biotech: the clinical catalysts (OVATION 3 enrollment beat, positive MRD data, DMC recommendation) are encouraging but the cash runway remains tight at ~$6.9M with a $7.0M H1 burn rate, suggesting another financing is likely before OVATION 3 completes in 2029. Watch for the R&D Day on September 23, 2026, for potential partnership or financing updates.
Price Chart
Executive Summary
Imunon reported Q2 2026 net loss of $2.8M ($0.54/share), slightly wider than the $2.7M loss in Q2 2025, with operating expenses flat at $2.8M. The key positive was continued strong enrollment momentum in the Phase 3 OVATION 3 trial and positive preliminary MRD study data, but the company's cash burn remains high ($7.0M operating cash used in H1 2026) and it raised $10M in June via preferred stock and secured notes, extending the cash runway but adding debt. The net loss per share improved year-over-year due to a significantly higher share count (5.2M vs 1.3M), masking the underlying cash burn rate.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $2.8M ($0.54/share) vs $2.7M ($2.15/share) in Q2 2025.
- Operating expenses were flat at $2.8M for both Q2 2026 and Q2 2025.
- Cash and cash equivalents were $6.9M as of June 30, 2026, down from $8.8M at Dec 31, 2025.
- Net cash used in operating activities for H1 2026 was $7.0M, up from $5.8M in H1 2025.
- Company raised $10M in June via 250 shares of non-redeemable preferred stock ($2.5M) and two secured promissory notes ($2.72M and $5.0M).
- Enrollment in the Phase 3 OVATION 3 trial continues to exceed planning assumptions; completion expected by H1 2029.
- Preliminary Phase 2 MRD study data showed deeper antitumor response (44% vs 67% MRD-positive rate) and higher ctDNA clearance (87.5% vs 62.5%).
- Independent Data Monitoring Committee recommended continuation of the Phase 3 OVATION 3 trial on June 23, 2026.
Financial Impact
Net loss of $2.8M for Q2 2026; cash burn of $7.0M in H1 2026; $10M financing completed in June 2026
Risk Factors
- Cash runway of $6.9M may be insufficient to complete Phase 3 enrollment without additional financing or partnership
- Phase 3 OVATION 3 trial completion not expected until H1 2029, creating long binary risk
- New debt of $7.7M (two secured notes) adds leverage and interest expense to a pre-revenue company
- Preliminary MRD data is from a small sample (9 patients per arm) and may not be reproducible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036985 |
| Document: form8-k.htm | 0001493152-26-036985 |
| Document: 0001493152-26-036985-index-headers.html | 0001493152-26-036985 |
| Document: 0001493152-26-036985-index.html | 0001493152-26-036985 |
| Document: 0001493152-26-036985.txt | 0001493152-26-036985 |
| 8-K Data (Synthetic) | 0001493152-26-036985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | S-1 | $1.22 | awaiting T+5 | — | $0.8567 (+29.78%) |
Oct 27, 2026 today | 8-K | $1.25 | awaiting T+5 | — | $0.8567 (−31.46%) |
Oct 21, 2026 6d ago | 8-K | $1.19 | awaiting T+5 | — | $0.8567 (−28.01%) |
Sep 29, 2026 28d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $0.8567 (+35.83%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $0.8567 (−46.79%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $0.8567 (−46.79%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $0.8567 (−54.43%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $0.8567 (−53.94%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $0.8567 (+59.20%) |
May 12, 2026 24w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $0.8567 (−68.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers